Compare GKOS & HXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | HXL |
|---|---|---|
| Founded | 1998 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.6B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | HXL |
|---|---|---|
| Price | $103.96 | $84.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $133.07 | $81.73 |
| AVG Volume (30 Days) | 662.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $507,442,000.00 | ★ $1,893,900,000.00 |
| Revenue This Year | $23.39 | $10.20 |
| Revenue Next Year | $27.46 | $12.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $45.28 |
| 52 Week High | $130.23 | $95.22 |
| Indicator | GKOS | HXL |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 39.62 |
| Support Level | $81.54 | $80.25 |
| Resistance Level | $106.52 | $84.64 |
| Average True Range (ATR) | 3.58 | 2.51 |
| MACD | -1.81 | -1.15 |
| Stochastic Oscillator | 14.28 | 0.36 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.